Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 3 Issue 12, December 2004

In This Issue

Top of page ⤴

Editorial

Top of page ⤴

News

Top of page ⤴

News in Brief

Top of page ⤴

Patent Watch

Top of page ⤴

Patent Primer

  • You are a biotech company that has just been granted a patent connected with drug discovery. What do you do with it? The costs of drug discovery and development are so prohibitive that only large companies have sufficient resources to proceed with such an undertaking. Therefore most biotech companies will need to involve a larger third party at some stage in order to develop the product and get it to market. When should your average biotech company try to tie the knot with a big pharma partner?

    • Luke Kempton
    Patent Primer
Top of page ⤴

An Audience With

Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Mohamed Muhsin
    • Joanne Graham
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Review Article

Top of page ⤴

Opinion

Top of page ⤴

Natureview

Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Quick links